Literature DB >> 34143327

Spray-Dried Inhalable Powder Formulations of Therapeutic Proteins and Peptides.

Basanth Babu Eedara1, Wafaa Alabsi1,2, David Encinas-Basurto1, Robin Polt2,3, Heidi M Mansour4,5,6.   

Abstract

Respiratory diseases are among the leading causes of morbidity and mortality worldwide. Innovations in biochemical engineering and understanding of the pathophysiology of respiratory diseases resulted in the development of many therapeutic proteins and peptide drugs with high specificity and potency. Currently, protein and peptide drugs are mostly administered by injections due to their large molecular size, poor oral absorption, and labile physicochemical properties. However, parenteral administration has several limitations such as frequent dosing due to the short half-life of protein and peptide in blood, pain on administration, sterility requirement, and poor patient compliance. Among various noninvasive routes of administrations, the pulmonary route has received a great deal of attention and is a better alternative to deliver protein and peptide drugs for treating respiratory diseases and systemic diseases. Among the various aerosol dosage forms, dry powder inhaler (DPI) systems appear to be promising for inhalation delivery of proteins and peptides due to their improved stability in solid state. This review focuses on the development of DPI formulations of protein and peptide drugs using advanced spray drying. An overview of the challenges in maintaining protein stability during the drying process and stabilizing excipients used in spray drying of proteins and peptide drugs is discussed. Finally, a summary of spray-dried DPI formulations of protein and peptide drugs, their characterization, various DPI devices used to deliver protein and peptide drugs, and current clinical status are discussed.

Entities:  

Keywords:  biologics; dry powder inhalers; inhalation; particle engineering design; respiratory

Mesh:

Substances:

Year:  2021        PMID: 34143327     DOI: 10.1208/s12249-021-02043-5

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   4.026


  39 in total

1.  Statistical modeling of protein spray drying at the lab scale.

Authors:  Kristin B Prinn; Henry R Costantino; Mark Tracy
Journal:  AAPS PharmSciTech       Date:  2002       Impact factor: 3.246

Review 2.  Particle engineering techniques for inhaled biopharmaceuticals.

Authors:  Sunday A Shoyele; Simon Cawthorne
Journal:  Adv Drug Deliv Rev       Date:  2006-08-12       Impact factor: 15.470

3.  Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs.

Authors:  Basanth Babu Eedara; Ian G Tucker; Zoran D Zujovic; Thomas Rades; Jason R Price; Shyamal C Das
Journal:  Eur J Pharm Sci       Date:  2019-06-17       Impact factor: 4.384

4.  The effect of operating and formulation variables on the morphology of spray-dried protein particles.

Authors:  Y F Maa; H R Costantino; P A Nguyen; C C Hsu
Journal:  Pharm Dev Technol       Date:  1997-08       Impact factor: 3.133

5.  Protective effect of sucrose on spray drying of oxyhemoglobin.

Authors:  P Labrude; M Rasolomanana; C Vigneron; C Thirion; B Chaillot
Journal:  J Pharm Sci       Date:  1989-03       Impact factor: 3.534

Review 6.  Molecular level insight into intra-solvent interaction effects on protein stability and aggregation.

Authors:  Diwakar Shukla; Curtiss P Schneider; Bernhardt L Trout
Journal:  Adv Drug Deliv Rev       Date:  2011-07-06       Impact factor: 15.470

7.  Feasibility study on spray-drying protein pharmaceuticals: recombinant human growth hormone and tissue-type plasminogen activator.

Authors:  M Mumenthaler; C C Hsu; R Pearlman
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

8.  Stability and surface activity of lactate dehydrogenase in spray-dried trehalose.

Authors:  M Adler; G Lee
Journal:  J Pharm Sci       Date:  1999-02       Impact factor: 3.534

9.  In vitro dissolution testing of respirable size anti-tubercular drug particles using a small volume dissolution apparatus.

Authors:  Basanth Babu Eedara; Ian G Tucker; Shyamal C Das
Journal:  Int J Pharm       Date:  2019-01-23       Impact factor: 5.875

Review 10.  The History of Therapeutic Aerosols: A Chronological Review.

Authors:  Stephen W Stein; Charles G Thiel
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-10-17       Impact factor: 2.849

View more
  5 in total

1.  Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.

Authors:  Wafaa Alabsi; Maria F Acosta; Fahad A Al-Obeidi; Meredith Hay; Robin Polt; Heidi M Mansour
Journal:  Pharmaceutics       Date:  2021-08-17       Impact factor: 6.321

2.  Inhalable Mannosylated Rifampicin-Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy.

Authors:  Juan M Galdopórpora; Camila Martinena; Ezequiel Bernabeu; Jennifer Riedel; Lucia Palmas; Ines Castangia; Maria Letizia Manca; Mariana Garcés; Juan Lázaro-Martinez; Maria Jimena Salgueiro; Pablo Evelson; Nancy Liliana Tateosian; Diego Andres Chiappetta; Marcela Analia Moretton
Journal:  Pharmaceutics       Date:  2022-04-28       Impact factor: 6.525

3.  Simultaneous Spray Drying for Combination Dry Powder Inhaler Formulations.

Authors:  Kimberly B Shepard; Amanda M Pluntze; David T Vodak
Journal:  Pharmaceutics       Date:  2022-05-26       Impact factor: 6.525

Review 4.  Localized delivery of nanomedicine and antibodies for combating COVID-19.

Authors:  Bin Tu; Yanrong Gao; Xinran An; Huiyuan Wang; Yongzhuo Huang
Journal:  Acta Pharm Sin B       Date:  2022-09-23       Impact factor: 14.903

Review 5.  Inhalation Delivery for the Treatment and Prevention of COVID-19 Infection.

Authors:  Basanth Babu Eedara; Wafaa Alabsi; David Encinas-Basurto; Robin Polt; Julie G Ledford; Heidi M Mansour
Journal:  Pharmaceutics       Date:  2021-07-14       Impact factor: 6.525

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.